G1 therapeutics, inc. (GTHX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities
Net loss

-129,518

-122,447

-111,097

-98,651

-88,830

-85,288

-78,178

-73,861

-68,186

-60,121

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

451

356

275

237

207

175

145

124

109

89

0

0

0

Stock-based compensation

17,372

16,449

15,240

14,075

12,435

10,225

8,008

5,772

4,440

3,394

0

0

0

Loss on disposal of fixed assets

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase in fair value of warrant activity

-

-

-

-

-

-

-

-

-

41

0

0

0

Change in operating assets and liabilities
Prepaid expenses and other assets

-996

219

149

902

-216

-113

704

569

-460

253

0

0

0

Accounts payable

1,871

248

3,220

-715

-1,267

-1,002

0

0

0

-

-

-

-

Accrued expenses and other liabilities

0

-

0

0

0

-

0

0

0

-

-

-

-

Deferred Rent

-

-

-

-

-

16

0

0

0

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in operating activities

-105,050

-99,571

-90,788

-82,472

-77,744

-74,307

-67,825

-64,771

-59,348

-50,519

0

0

0

Cash flows from investing activities
Purchases of property and equipment

-

2,716

1,727

917

854

709

622

444

352

294

0

0

0

Net cash used in investing activities

-

-2,716

-2,227

-1,417

-854

-709

-622

-444

-352

-294

0

0

0

Cash flows from financing activities
Proceeds from stock options and warrants exercised

2,655

2,705

2,702

1,836

1,419

1,797

1,616

1,110

861

215

0

0

0

Proceeds from public offering, net of underwriting fees and commissions

-

-

-

-

-

339,589

0

0

0

-

-

-

-

Payment of public offering costs

-

-

-

-

-

892

614

826

1,428

1,398

0

0

0

Net cash provided by financing activities

2,655

2,705

2,424

220,573

232,008

340,494

340,591

120,767

216,360

107,320

0

0

0

Net change in cash and cash equivalents

-104,895

-99,582

-90,591

136,684

153,410

265,478

272,144

55,552

156,660

56,507

0

0

0

Non-cash investing and financing activities
Upfront project costs and other current assets in accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

4,757

0

0

0

Purchases of equipment in accounts payable and accrued expenses

-

41

1,161

115

145

100

0

0

0

-

-

-

-

Costs for public offering in accounts payable and accrued expenses

-

-

-

-

-

-

0

0

0

-

-

0

0